177 related articles for article (PubMed ID: 29940218)
1. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
Bot CT; Juhasz K; Haeusermann F; Polonchuk L; Traebert M; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
[TBL] [Abstract][Full Text] [Related]
2. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
[TBL] [Abstract][Full Text] [Related]
3. Safety pharmacology studies using EFP and impedance.
Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
[TBL] [Abstract][Full Text] [Related]
5. Proarrhythmic risk assessment using conventional and new in vitro assays.
Goineau S; Castagné V
Regul Toxicol Pharmacol; 2017 Aug; 88():1-11. PubMed ID: 28506844
[TBL] [Abstract][Full Text] [Related]
6. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
[TBL] [Abstract][Full Text] [Related]
8. Functional Impact of BeKm-1, a High-Affinity hERG Blocker, on Cardiomyocytes Derived from Human-Induced Pluripotent Stem Cells.
De Waard S; Montnach J; Ribeiro B; Nicolas S; Forest V; Charpentier F; Mangoni ME; Gaborit N; Ronjat M; Loussouarn G; Lemarchand P; De Waard M
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998413
[TBL] [Abstract][Full Text] [Related]
9. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
10. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
[TBL] [Abstract][Full Text] [Related]
11. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
[TBL] [Abstract][Full Text] [Related]
12. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
Blinova K; Dang Q; Millard D; Smith G; Pierson J; Guo L; Brock M; Lu HR; Kraushaar U; Zeng H; Shi H; Zhang X; Sawada K; Osada T; Kanda Y; Sekino Y; Pang L; Feaster TK; Kettenhofen R; Stockbridge N; Strauss DG; Gintant G
Cell Rep; 2018 Sep; 24(13):3582-3592. PubMed ID: 30257217
[TBL] [Abstract][Full Text] [Related]
13. Application of optical action potentials in human induced pluripotent stem cells-derived cardiomyocytes to predict drug-induced cardiac arrhythmias.
Lu HR; Hortigon-Vinagre MP; Zamora V; Kopljar I; De Bondt A; Gallacher DJ; Smith G
J Pharmacol Toxicol Methods; 2017 Sep; 87():53-67. PubMed ID: 28501647
[TBL] [Abstract][Full Text] [Related]
14. Detection of Drug-Induced Torsades de Pointes Arrhythmia Mechanisms Using hiPSC-CM Syncytial Monolayers in a High-Throughput Screening Voltage Sensitive Dye Assay.
da Rocha AM; Creech J; Thonn E; Mironov S; Herron TJ
Toxicol Sci; 2020 Feb; 173(2):402-415. PubMed ID: 31764978
[TBL] [Abstract][Full Text] [Related]
15. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
Satsuka A; Kanda Y
Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
[TBL] [Abstract][Full Text] [Related]
18. Application of human induced pluripotent stem cell-derived cardiomyocytes sheets with microelectrode array system to estimate antiarrhythmic properties of multi-ion channel blockers.
Izumi-Nakaseko H; Hagiwara-Nagasawa M; Naito AT; Goto A; Chiba K; Sekino Y; Kanda Y; Sugiyama A
J Pharmacol Sci; 2018 Aug; 137(4):372-378. PubMed ID: 30126708
[TBL] [Abstract][Full Text] [Related]
19. Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
Jæger KH; Wall S; Tveito A
PLoS Comput Biol; 2021 Feb; 17(2):e1008089. PubMed ID: 33591962
[TBL] [Abstract][Full Text] [Related]
20. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
Gibson JK; Yue Y; Bronson J; Palmer C; Numann R
J Pharmacol Toxicol Methods; 2014; 70(3):255-67. PubMed ID: 25219538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
